Masahiro Yamamoto

Researcher Name Resolver ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 7

Top Topics

Oxidative Stress

Cancer Stem Cells

Small Cell Lung Cancer

Top Venues

Life (Basel, Switzerland)

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Masahiro Yamamoto, Shuhei Suzuki, Keita Togashi, Asuka Sugai, Masashi Okada, Chifumi Kitanaka
Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins. Cancers 14 (7) (2022)
Shuhei Suzuki, Masahiro Yamamoto, Tomomi Sanomachi, Keita Togashi, Asuka Sugai, Shizuka Seino, Takashi Yoshioka, Masashi Okada, Chifumi Kitanaka
Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction. Life (Basel, Switzerland) 11 (9) (2021)
Masahiro Yamamoto, Tomomi Sanomachi, Shuhei Suzuki, Keita Togashi, Asuka Sugai, Shizuka Seino, Atsushi Sato, Masashi Okada, Chifumi Kitanaka
Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax. Neuro-oncology advances 3 (1) (2021)
Masashi Okada, Shuhei Suzuki, Keita Togashi, Asuka Sugai, Masahiro Yamamoto, Chifumi Kitanaka
Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma Xenografts. International journal of molecular sciences 22 (21) (2021)
Kenta Kuramoto, Masahiro Yamamoto, Shuhei Suzuki, Keita Togashi, Tomomi Sanomachi, Chifumi Kitanaka, Masashi Okada
Inhibition of the Lipid Droplet-Peroxisome Proliferator-Activated Receptor α Axis Suppresses Cancer Stem Cell Properties. Genes 12 (1) (2021)
Shuhei Suzuki, Masahiro Yamamoto, Tomomi Sanomachi, Keita Togashi, Asuka Sugai, Shizuka Seino, Takashi Yoshioka, Chifumi Kitanaka, Masashi Okada
Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction. Cancers 11 (7) (2019)
Tomomi Sanomachi, Shuhei Suzuki, Keita Togashi, Asuka Sugai, Shizuka Seino, Masashi Okada, Takashi Yoshioka, Chifumi Kitanaka, Masahiro Yamamoto
Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs. Cancers 11 (10) (2019)